<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701881</url>
  </required_header>
  <id_info>
    <org_study_id>1-2014-0072</org_study_id>
    <nct_id>NCT02701881</nct_id>
  </id_info>
  <brief_title>Comparison of the PrimAry Long Versus Short Coverage With Drug-Eluting Stents for Long FemoRopopliteal Artery DiseasE (PARADE II): Investigator-initiated Clinical Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Prospective, randomized, controlled, multi-center study

        -  A total of 220 subjects with long femoropopliteal lesions will be included according to
           inclusion and exclusion criteria.

        -  Patients will be randomized in a 1:1 manner into long stenting group versus short
           stenting group. and treated with Zilver PTX for long femoropopliteal lesions

        -  Patients will be followed clinically for 1 year after the procedure.

        -  Image study follow-up (Duplex US or CT angiography) will be performed at 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency rate</measure>
    <time_frame>12 months</time_frame>
    <description>Absence of restenosis &gt;50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization rate</measure>
    <time_frame>12 months</time_frame>
    <description>repeat intervention or surgical treatment due to loss of patency at the target vessel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Femoropopliteal Artery Disease</condition>
  <arm_group>
    <arm_group_label>Long stenting group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Short stenting group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Long stenting using drug-eluting stent (Zilver PTX)</intervention_name>
    <description>Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty</description>
    <arm_group_label>Long stenting group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spot stenting using drug-eluting stent (Zilver PTX)</intervention_name>
    <description>Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion</description>
    <arm_group_label>Short stenting group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical criteria:

               1. Age 19 years of older

               2. Symptomatic peripheral artery disease:

                    1. Moderate or severe claudication (Rutherford category 2 or 3)

                    2. Critical limb ischemia (Rutherford category 4 or 5)

               3. Patients with signed informed consent

          -  Anatomical criteria:

               1. Target lesion length â‰¥150 mm by angiographic estimation

               2. Stenosis of more than 50% in femoropopliteal artery

               3. At least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel.

        Exclusion Criteria:

          -  A. Clinical criteria

               1. Acute critical limb ischemia

               2. Severe critical limb ischemia (Rutherford category 6)

               3. Major bleeding history within prior 2 months

               4. Known hypersensitivity or contraindication to any of the following medications:
                  heparin, aspirin, clopidogrel or contrast agents

               5. Age &gt; 85 years

               6. Severe hepatic dysfunction (&gt; 3 times normal reference values)

               7. Significant renal dysfunction (Serum creatinine &gt; 2.0 mg/dl

               8. Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding
                  diathesis

               9. LVEF &lt;40% or clinically overt congestive heart failure

              10. Pregnant women or women with potential childbearing

              11. Life expectancy &lt;1 year due to comorbidity

          -  Angiographic criteria

               1. Previous bypass surgery or stenting of the superficial femoral artery

               2. Untreated inflow disease of the ipsilateral pelvic arteries (more than
                  50%stenosis or or occlusion

               3. Popliteal artery stenosis &gt;50% at P2 or P3 segment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Hoon Choi, MD</last_name>
      <phone>82 2 2228 8449</phone>
      <email>cdhlyj@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Femoropopliteal Artery</keyword>
  <keyword>Drug-eluting Stent</keyword>
  <keyword>Endovascular Therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

